All In Biotech

Drug Trial Radar · NCT03056326

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects

A Phase I, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6333 After Single and Repeated Ascending Doses in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Nov 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Nov 2016

Primary completion

Jul 2017

Study completion Jul 2017

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Feb 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Human Neutrophil Elastase (HNE) plays a pivotal role in innate immunity and in neutrophilic lung inflammation that characterized many diseases. CHF 6333 is a potent and 24h-durable inhibitor of HNE, developed as Dry Powder Inhaler (DPI) formulation. This study is designed to investigate the tolerability, safety and pharmacokinetics of inhaled CHF6333 DPI in healthy male subjects. The study will comprise two parts: Part 1 will consist of two alternated cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of Single Ascending Dose (SAD) of CHF6333. Part 2 will consist of four sequential cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of Multiple Ascending Dose (MAD) of CHF6333

Conditions

  • Non-Cystic Fibrosis Bronchiectasis
  • Cystic Fibrosis

Interventions

  • CHF6333 (Part 1 - SAD)Drug

    Single doses of CHF6333 at each period

  • Placebo (Part 1 - SAD)Drug

    Single doses of placebo matching CHF6333 at each period

  • CHF6333 (Part 2 - MAD)Drug

    once daily multiple doses of CHF6333 for 14 days

  • Placebo (Part 2 - MAD)Drug

    once daily multiple doses of placebo matching CHF6333 for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Part 1 from Day 1 to 5, Part 2 from Day 1 to 15
  2. Change in Vital signsTime frame: Part 1 from Day 1 to 5, Part 2 from Day 1 to 15
  3. Heart RateTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
  4. QTcF intervalTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
  5. PR intervalTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
  6. QRS intervalTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
  7. Holter recording abnormalitiesTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
  8. FEV1Time frame: Part 1 Day 1-2, Part 2 Day 1-14-15
  9. Clinical chemistry and haematologyTime frame: Part 1 Day 1-5, Part 2 Day 1-15
  10. UrinalysisTime frame: Part 1 Day 1-5, Part 2 Day 1-15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Life Sciences

    Antwerp, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.